Why is Moderna stock surging today?

Moderna stock surged 8.5% in pre-open trading after the Cambridge, Massachusetts-based biotech posted third-quarter 2026 results that far exceeded analyst forecasts, with revenue of $1.31 billion — nearly 50% above the consensus estimate of roughly $885 million — and earnings per share of $0.38 against an expected loss of more than $1.10. The company swung to a net profit of $162 million compared with a net loss of approximately $200 million in the same period a year earlier, marking a decisive return to profitability. Revenue grew 29% year-over-year, driven primarily by stronger international COVID-19 vaccine sales and deliveries under long-term strategic government partnerships.

Equally impactful was the company’s decision to sharply raise its full-year 2026 revenue growth guidance to a range of 15%–25%, more than doubling the upper end of its prior outlook of up to 10% growth. CEO Stéphane Bancel credited "the new product and the diversification of geography" as the key forces behind the quarter’s strength. The company also improved its operating expense outlook by approximately $200 million and lifted its expected year-end cash balance to $8.1–$8.3 billion, reinforcing confidence in the balance sheet. Adding to the positive sentiment, early Phase 1/2 data for mRNA-2808 — Moderna’s novel multiplexed mRNA therapy for relapsed or refractory multiple myeloma — showed a roughly 36% response rate among heavily pretreated patients with no dose-limiting toxicities, a result that had already begun generating buzz earlier in the week.

The broader market provided a constructive backdrop, with the NASDAQ gaining 1.6% and the S&P 500 adding 0.4%, reflecting an appetite for growth-oriented names. Healthcare stocks more broadly also rose on the session, amplifying the positive read-through for Moderna. The company’s pipeline momentum — including Health Canada’s recent authorization of its mFLUSIVA influenza vaccine and mCOFLU combination flu-COVID vaccine, making Canada the first country to approve both products — further underscored the narrative of a company diversifying well beyond its COVID-19 roots.

Taken together, a massive earnings beat, a dramatically upgraded revenue outlook, a return to profitability, and continued oncology pipeline progress converged to produce one of Moderna’s strongest pre-market sessions in recent memory, pushing the stock to trade at its 52-week high of $261 and beyond.